Kura Oncology (KURA) News Today $8.90 -0.11 (-1.22%) (As of 12:09 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Kura Oncology (NASDAQ:KURA) Reaches New 52-Week Low - What's Next?Kura Oncology (NASDAQ:KURA) Hits New 1-Year Low - Here's What HappenedDecember 18, 2024 | marketbeat.comKura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)December 18, 2024 | seekingalpha.comKura Oncology’s Promising Clinical Advances and Strategic Pipeline Developments Justify Buy RatingDecember 11, 2024 | markets.businessinsider.comJonathan Chang Recommends ‘Buy’ on Kura Oncology Amid Promising Ziftomenib Advancements in AML TreatmentDecember 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kura Oncology Amid Promising Trial ResultsDecember 10, 2024 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on Kura Oncology (KURA)December 9, 2024 | markets.businessinsider.comPromising Clinical Trial Developments in Kura Oncology’s Ziftomenib for AML TreatmentDecember 9, 2024 | markets.businessinsider.comKura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual MeetingDecember 9, 2024 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Kura Oncology (KURA)December 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Kura Oncology (KURA), Cooper Co (COO) and Ironwood Pharma (IRWD)December 6, 2024 | markets.businessinsider.comKura Oncology management to meet with Cantor FitzgeraldDecember 5, 2024 | markets.businessinsider.comWhy Is Kura Oncology, Inc. (KURA) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?December 5, 2024 | msn.comKura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Recommendation of "Buy" from BrokeragesKura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has been assigned a consensus rating of "Buy" from the eleven brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a stronDecember 5, 2024 | marketbeat.comJefferies Sticks to Its Buy Rating for Kura Oncology (KURA)December 2, 2024 | markets.businessinsider.comKura Oncology to Host Virtual Investor Event on December 9, 2024December 2, 2024 | globenewswire.comPharma giant Roche to buy San Diego biotech for up to $1.5BDecember 1, 2024 | msn.comStifel Nicolaus Keeps Their Hold Rating on Kura Oncology (KURA)November 26, 2024 | markets.businessinsider.comKura Oncology to Participate in JMP Securities Hematology and Oncology SummitNovember 25, 2024 | globenewswire.comFY2025 EPS Estimate for Kura Oncology Raised by AnalystKura Oncology, Inc. (NASDAQ:KURA - Free Report) - Equities research analysts at Brookline Capital Management boosted their FY2025 earnings per share (EPS) estimates for Kura Oncology in a research report issued to clients and investors on Thursday, November 21st. Brookline Capital Management analNovember 25, 2024 | marketbeat.comLeerink Partnrs Expects Higher Earnings for Kura OncologyKura Oncology, Inc. (NASDAQ:KURA - Free Report) - Stock analysts at Leerink Partnrs increased their FY2024 earnings per share estimates for shares of Kura Oncology in a research report issued to clients and investors on Thursday, November 21st. Leerink Partnrs analyst J. Chang now forecasts thatNovember 25, 2024 | marketbeat.comKura Oncology (KURA) Gets a Hold from ScotiabankNovember 23, 2024 | markets.businessinsider.comKura Oncology, Inc. (KURA): Among the Most Promising Cancer Stocks According to Hedge FundsNovember 23, 2024 | insidermonkey.comKura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26%November 22, 2024 | msn.comKura Oncology’s Strategic Developments and Partnership with Kyowa Kirin Justify Buy Rating, Despite Initial Stock DipNovember 22, 2024 | markets.businessinsider.comBofA lowers Kura Oncology price target to $29, sees buying opportunityNovember 22, 2024 | markets.businessinsider.comKura Oncology (NASDAQ:KURA) Sees Strong Trading Volume on Analyst UpgradeKura Oncology (NASDAQ:KURA) Sees Unusually-High Trading Volume After Analyst UpgradeNovember 22, 2024 | marketbeat.comBank of America Has Lowered Expectations for Kura Oncology (NASDAQ:KURA) Stock PriceBank of America lowered their price target on shares of Kura Oncology from $36.00 to $29.00 and set a "buy" rating on the stock in a report on Friday.November 22, 2024 | marketbeat.comKura selling off on loss of acquisition premium, says TD CowenNovember 22, 2024 | markets.businessinsider.comKura Oncology (KURA) Gets a Hold from Stifel NicolausNovember 22, 2024 | markets.businessinsider.comKura Oncology (KURA) Gets a Hold from Stifel NicolausNovember 22, 2024 | markets.businessinsider.comKura Oncology price target lowered to $34 from $37 at WedbushNovember 22, 2024 | markets.businessinsider.comKura Oncology price target lowered to $34 from $37 at WedbushNovember 22, 2024 | markets.businessinsider.comKura Oncology: A Contender In The Field Of Precision MedicineNovember 22, 2024 | seekingalpha.comKura Crashes 37% After $1.53 Billion Deal Slams The Door On A TakeoverNovember 22, 2024 | msn.comKura Oncology Stock Slips Following Collaboration With Kyowa: Retail Turns Extremely BullishNovember 21, 2024 | msn.comKura Crashes 35% After $1.53 Billion Deal Slams The Door On A TakeoverNovember 21, 2024 | msn.comKura Oncology (NASDAQ:KURA) Price Target Raised to $37.00HC Wainwright increased their price objective on shares of Kura Oncology from $32.00 to $37.00 and gave the company a "buy" rating in a research report on Thursday.November 21, 2024 | marketbeat.comKura Oncology partners Kyowa Kirin to advance AML treatmentNovember 21, 2024 | yahoo.comKura stock slides 17% on Kyowa Kirin deal for ziftomenibNovember 20, 2024 | msn.comKura Oncology to partner with Kyowa Kirin for blood cancer therapyNovember 20, 2024 | reuters.comKura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute LeukemiasNovember 20, 2024 | globenewswire.comKura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute LeukemiasNovember 20, 2024 | prnewswire.comStockNews.com Downgrades Kura Oncology (NASDAQ:KURA) to SellStockNews.com cut shares of Kura Oncology from a "hold" rating to a "sell" rating in a research report on Wednesday.November 20, 2024 | marketbeat.comKura Oncology (NASDAQ:KURA) Earns Market Outperform Rating from JMP SecuritiesJMP Securities restated a "market outperform" rating and issued a $32.00 target price on shares of Kura Oncology in a research note on Tuesday.November 19, 2024 | marketbeat.comKura Oncology: A Compelling Buy Amidst Growth Potential and Strategic AdvancementsNovember 19, 2024 | markets.businessinsider.comPromising Developments and Strategic Advantages Elevate Kura Oncology’s ProspectsNovember 18, 2024 | markets.businessinsider.comPositive Outlook on Kura Oncology’s Growth Potential Amid Competitive LandscapeNovember 17, 2024 | markets.businessinsider.comKura Oncology Positioned for Growth with Promising Menin Inhibitor Ziftomenib Amidst Competitor ChallengesNovember 14, 2024 | markets.businessinsider.comOptimistic Buy Rating for Kura Oncology: Ziftomenib’s Competitive Edge and Strong Safety ProfileNovember 14, 2024 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Kura Oncology (NASDAQ:KURA)HC Wainwright reiterated a "buy" rating and issued a $32.00 price target on shares of Kura Oncology in a research note on Wednesday.November 13, 2024 | marketbeat.com Get Kura Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter. Email Address Mysterious drone activity triggers massive 1,366% surge (Ad)If mysterious drones buzzing over the East Coast weren’t on your radar this year, you’re not alone. But here’s what you really need to know: An early warning signal tipped off investors to a tiny drone stock that later skyrocketed 1,366%. 👉 Click here now to see how this signal works. KURA Media Mentions By Week KURA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KURA News Sentiment▼0.610.60▲Average Medical News Sentiment KURA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KURA Articles This Week▼26▲KURA Articles Average Week Get Kura Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MRUS News ACAD News TWST News MOR News VCEL News SWTX News ZLAB News KYMR News GMTX News VERA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KURA) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kura Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
